Skip to main content
Fig. 2 | Cardiovascular Diabetology

Fig. 2

From: Major adverse cardiovascular and limb events in patients with diabetes and concomitant peripheral artery disease treated with sodium glucose cotransporter 2 inhibitor versus dipeptidyl peptidase-4 inhibitor

Fig. 2

Cumulative incidence curves of outcomes for patients with concomitant type-2 diabetes mellitus (T2DM) and peripheral artery disease (PAD) treated with SGLT2i versus DPP4i after propensity score matching (PSM). Cumulative incidence curves of effectiveness outcomes including ischemic stroke (IS) (a), acute myocardial infarction (AMI) (b), congestive heart failure (CHF) (c), lower extremity revascularization (d) or amputation (e), all-cause mortality (f), and cardiovascular mortality (g) for patients with T2DM and concomiant PAD taking SGLT2i versus DPP4i after PSM are presented. SGLT2i were associated with lower cumulative risks of CHF, all-cause and cardiovascular mortality, and lower extremity revascularization or amputation compared with DPP4i among patients with T2DM and concomitant PAD. Abbreviations: AMI acute myocardial infarction, CHF congestive heart failure, IS ischemic stroke, PSM propensity score matching. Other abbreviations are the same as those in Fig. 1

Back to article page

Cardiovascular Diabetology

ISSN: 1475-2840